Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL
Clinical trial NCT02462538 · TERMINATED
Trial details
- NCT number
- NCT02462538
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-11-03
- Primary completion
- 2021-11-03
- Enrollment
- 3
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.